Ariel Beresniak (born 3 December 1961) is a Swiss specialist in Public Health and Health Economics, author of reference books and scientific articles in modeling and decision-making analyses.
Biography
Beresniak is a physician specialized in Public Health from the Faculty of Medicine at University of Marseille, France . He also obtained a master's degree in Economics and a PhD in applied mathematics in Economics at the Claude-Bernard University (France), and an Accreditation to Supervise Research (Habilitation a Diriger des Recherches). Beresniak was Chief Medical Officer of Epidemic Surveillance in Gabon in 1989 before contributing to implement medico-economic methodologies in the pharmaceutical industry for assessing the value of innovative treatments. He was Head of Health Economics for Glaxo-Wellcome (1993-1999) and Global Head of Pharmacoeconomics for Serono International (1999-2004). Since 2005, Beresniak is CEO o
Data Mining International He has been short-term consultant for the World Health Organization and the European commission in the fields of Public health and Health Economics. He is visiting Professor at the
Plekhanov Russian Economic University.
Scientific contribution
Beresniak is author of the reference book "Health Economics" published in French and Portuguese. He publishes two dictionaries: one dictionary of Health Economics published in French and Spanish, and one dictionary of terms used in health industries published in French. Beresniak is also coauthor of "Understanding Pharmacoeconomics" published in French and "Pharmacoeconomics" published in Japanese. Beresniak is known to have led th
ECHOUTCOMEproject, a European Commission funded research, establishing that the
QALY
The quality-adjusted life year (QALY) is a generic measure of disease burden, including both the quality and the quantity of life lived. It is used in economic evaluation to assess the value of medical interventions. One QALY equates to one year ...
indicator (Quality Adjusted Life Years) is not scientifically validated to be used in Decision making and could lead to divergent results with the same dataset. These findings have generated an international controversy because the QALY indicator is still currently promoted as reference case by some national health technology assessment agencies such as th
NICE(
National Institute for Health and Care Excellence
The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body of the Department of Health and Social Care in England that publishes guidelines in four areas:
* the use of health technologies withi ...
) in the UK.
Beresniak was also project leader of th
FLURESPproject, a European Commission funded research, with the objective to compare
cost-effectiveness of 18 public health interventions against human pandemic influenza. Beresniak confirmed the value of universal influenza vaccination of the entire population, which is a strategy appearing more "cost-effective" compared to vaccination limited to "at-risk groups" as still widely recommended by health authorities. Beresniak also found that the most effective measures against influenza epidemic mortality are the development of more intensive care units equipped with
ECMO
Extracorporeal membrane oxygenation (ECMO), also known as extracorporeal life support (ECLS), is an extracorporeal technique of providing prolonged cardiac and respiratory support to persons whose heart and lungs are unable to provide an adequat ...
extracorporeal oxygenation platforms for managing
acute respiratory distress syndrome (ARDS).
[Ariel Beresniak, Caterina Rizzo, John Oxford et Paweł Goryński, « Cost-effectiveness of public health interventions against human influenza pandemics in France: a methodological contribution from the FLURESP European Commission project », European Journal of Public Health, 5 mai 2019, ckz074 (ISSN 1101-1262 et 1464-360X, DOI 10.1093/eurpub/ckz074]
References
{{DEFAULTSORT:Beresniak, Ariel
Living people
1961 births
Health economists
Data miners
Swiss public health doctors